Erez Rechavi1,2,3, Atar Lev1,3, Eran Eyal4,3, Ortal Barel4,3, Nitzan Kol4,3, Sarit Farage Barhom4,3, Ben Pode-Shakked2,3, Yair Anikster2,5,3, Raz Somech6,7,8, Amos J Simon9,10,11,12. 1. Pediatric Department A and the Immunology Service, Jeffrey Modell Foundation Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. 2. Edmond and Lily Safra Children's Hospital, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. 3. Sheba Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. 4. Cancer Research Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. 5. Metabolic Disease Unit, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. 6. Pediatric Department A and the Immunology Service, Jeffrey Modell Foundation Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. rsomech@hotmail.com. 7. Edmond and Lily Safra Children's Hospital, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. rsomech@hotmail.com. 8. Sheba Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. rsomech@hotmail.com. 9. Pediatric Department A and the Immunology Service, Jeffrey Modell Foundation Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. amos.simon@sheba.health.gov.il. 10. Cancer Research Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. amos.simon@sheba.health.gov.il. 11. Institute of Hematology, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. amos.simon@sheba.health.gov.il. 12. Sheba Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Hashomer, Ramat Gan, Israel. amos.simon@sheba.health.gov.il.
Abstract
PURPOSE: Immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome is an extremely rare autosomal recessive disease. The immune phenotype is characterized by hypogammaglobulinemia in the presence of B cells. T cell lymphopenia also develops in some patients. We sought to further investigate the immune defect in an ICF patient with a novel missense mutation in DNMT3B and a severe phenotype. METHODS: Patient lymphocytes were examined for subset counts, immunoglobulin levels, T and B cell de novo production (via excision circles) and receptor repertoire diversity. Mutated DNMT3B protein structure was modeled to assess the effect of a mutation located outside of the catalytic region on protein function. RESULTS: A novel homozygous missense mutation, Ala585Thr, was found in DNMT3B. The patient had decreased B cell counts with hypogammaglobulinemia, and normal T cell counts. CD4+ T cells decreased over time, leading to an inversion of the CD4+ to CD8+ ratio. Excision circle copy numbers were normal, signifying normal de novo lymphocyte production, but the ratio between naïve and total B cells was low, indicating decreased in vivo B cell replication. T and B cell receptor repertoires displayed normal diversity. Computerized modeling of the mutated Ala585 residue suggested reduced thermostability, possibly affecting the enzyme kinetics. CONCLUSIONS: Our results highlight the existence of a T cell defect that develops over time in ICF patient, in addition to the known B cell dysfunction. With intravenous immunoglobulin (IVIG) treatment ameliorating the B cell defect, the extent of CD4+ lymphopenia may determine the severity of ICF immunodeficiency.
PURPOSE:Immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome is an extremely rare autosomal recessive disease. The immune phenotype is characterized by hypogammaglobulinemia in the presence of B cells. T cell lymphopenia also develops in some patients. We sought to further investigate the immune defect in an ICFpatient with a novel missense mutation in DNMT3B and a severe phenotype. METHODS:Patient lymphocytes were examined for subset counts, immunoglobulin levels, T and B cell de novo production (via excision circles) and receptor repertoire diversity. Mutated DNMT3B protein structure was modeled to assess the effect of a mutation located outside of the catalytic region on protein function. RESULTS: A novel homozygous missense mutation, Ala585Thr, was found in DNMT3B. The patient had decreased B cell counts with hypogammaglobulinemia, and normal T cell counts. CD4+ T cells decreased over time, leading to an inversion of the CD4+ to CD8+ ratio. Excision circle copy numbers were normal, signifying normal de novo lymphocyte production, but the ratio between naïve and total B cells was low, indicating decreased in vivo B cell replication. T and B cell receptor repertoires displayed normal diversity. Computerized modeling of the mutated Ala585 residue suggested reduced thermostability, possibly affecting the enzyme kinetics. CONCLUSIONS: Our results highlight the existence of a T cell defect that develops over time in ICFpatient, in addition to the known B cell dysfunction. With intravenous immunoglobulin (IVIG) treatment ameliorating the B cell defect, the extent of CD4+ lymphopenia may determine the severity of ICF immunodeficiency.
Authors: Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo Journal: Genome Res Date: 2010-07-19 Impact factor: 9.043
Authors: Jessica C de Greef; Jun Wang; Judit Balog; Johan T den Dunnen; Rune R Frants; Kirsten R Straasheijm; Caner Aytekin; Mirjam van der Burg; Laurence Duprez; Alina Ferster; Andrew R Gennery; Giorgio Gimelli; Ismail Reisli; Catharina Schuetz; Ansgar Schulz; Dominique F C M Smeets; Yves Sznajer; Cisca Wijmenga; Marja C van Eggermond; Monique M van Ostaijen-Ten Dam; Arjan C Lankester; Maarten J D van Tol; Peter J van den Elsen; Corry M Weemaes; Silvère M van der Maarel Journal: Am J Hum Genet Date: 2011-05-19 Impact factor: 11.025
Authors: M M Hagleitner; A Lankester; P Maraschio; M Hultén; J P Fryns; C Schuetz; G Gimelli; E G Davies; A Gennery; B H Belohradsky; R de Groot; E J A Gerritsen; T Mattina; P J Howard; A Fasth; I Reisli; D Furthner; M A Slatter; A J Cant; G Cazzola; P J van Dijken; M van Deuren; J C de Greef; S M van der Maarel; C M R Weemaes Journal: J Med Genet Date: 2007-09-24 Impact factor: 6.318
Authors: Peter E Thijssen; Yuya Ito; Giacomo Grillo; Jun Wang; Guillaume Velasco; Hirohisa Nitta; Motoko Unoki; Minako Yoshihara; Mikita Suyama; Yu Sun; Richard J L F Lemmers; Jessica C de Greef; Andrew Gennery; Paolo Picco; Barbara Kloeckener-Gruissem; Tayfun Güngör; Ismail Reisli; Capucine Picard; Kamila Kebaili; Bertrand Roquelaure; Tsuyako Iwai; Ikuko Kondo; Takeo Kubota; Monique M van Ostaijen-Ten Dam; Maarten J D van Tol; Corry Weemaes; Claire Francastel; Silvère M van der Maarel; Hiroyuki Sasaki Journal: Nat Commun Date: 2015-07-28 Impact factor: 14.919
Authors: Caitlin M Burk; Kara E Coffey; Emily M Mace; Bret L Bostwick; Ivan K Chinn; Zeynep H Coban-Akdemir; Shalini N Jhangiani; James R Lupski; Damara Ortiz; Jessie L Barnum; Steven W Allen; Leanna-Marie Robertson; Jordan S Orange; Hey J Chong Journal: J Allergy Clin Immunol Pract Date: 2019-09-11